NCT06474377View on ClinicalTrials.gov

Clinical Trial of PCV24 in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

June 21, 2024

Primary Completion Date

August 26, 2024

Study Completion Date

February 26, 2025

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Sinovac PCV24 formulation 1

One dose of Sinovac PCV24 formulation 1（0.5mL）

BIOLOGICAL

Sinovac PCV24 formulation 2

One dose of Sinovac PCV24 formulation 2（0.5mL）

BIOLOGICAL

Pneumovax®

One dose of Pneumovax® (0.5 mL) contains 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F saccharides.

BIOLOGICAL

Placebo

0.5 mL of 0.9%NaCl solution (normal saline)

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY